4.26.2012

Phase 3 Results for GE Healthcare Imaging Agent Flutemetamol Presented at American Academy of Neurology Meeting

NEW ORLEANS, Apr 25, 2012 (BUSINESS WIRE) -- GE Healthcare today announced results from four pooled brain biopsy studies, as well as key results from a brain autopsy study, of the investigational PET amyloid imaging agent, [(18)F]flutemetamol.(1) The data showed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between [(18)F]flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology. The data confirm the potential of [(18)F]flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease (AD), in living patients.

These data are being presented as part of the Emerging Science Program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012, and support an application for regulatory approval of [(18)F]flutemetamol, which is intended to be filed later this year. [(18)F]flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid.

"Currently, the standard for definitively confirming AD is through detection of pathology, including amyloid plaque in the brain during autopsy," said David Wolk, MD, Assistant Professor of Neurology in the Cognitive Neurology Division, Department of Neurology, University of Pennsylvania, presenter and lead investigator for the biopsy study.

GE Healthcare

2 comments:

Market Research Reports said...

I truly like to read your post. Thank you so much for taking the time to share such nice information. I definitely add this great post in my article section.

MRI systems market

Unknown said...

Easybookmylab is one stop solution for all type of MRI scan in Delhi to guide and advice about the best available MRI Scan centres in Delhi. | For MRI scan test price